8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 231
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director | 744.02k | N/A | 1965 |
Dr. David J. D. Sourdive Ph.D. | Deputy CEO, Exec. VP of CMC & Manufacturing and Directorr | 528.92k | N/A | 1967 |
Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer | N/A | N/A | 1977 |
Valerie Cros | Principal Financial Officer & Principal Accounting Officer | N/A | N/A | N/A |
Mr. Jean Charles Epinat | Chief Technological Officer | N/A | N/A | N/A |
Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer | N/A | N/A | 1963 |
Mr. Stephan Reynier M.Sc., MSc | Chief Regulatory & Pharmaceutical Compliance Officer | N/A | N/A | 1969 |
Ms. Marie-Bleuenn Terrier | Gen. Counsel & Sec. of the Board of Directors | N/A | N/A | 1982 |
Pascalyne Wilson | Director of Communications | N/A | N/A | N/A |
Ms. Kyung Nam-Wortman | Exec. VP & Chief HR Officer | N/A | N/A | 1970 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A.’s ISS governance QualityScore as of 1 September 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 6.